Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07339943 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness

Study acronym: MicroUSgFLA
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later May 31, 2026 → May 31, 2028
See other at-risk trials from University Health Network, Toronto

Record History

  1. Primary completion pushed from May 31, 2026 to May 31, 2028 Completion pushed from Dec 31, 2027 to Dec 31, 2028 · Eligibility criteria expanded, about 22 words · Secondary endpoints: details revised at 3 of 3 entries · 1 more Show 4 more changesShow less
    • Completion pushed from Dec 31, 2027 to Dec 31, 2028
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Publications: details revised at 18 of 18 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk prostate cancer (PCa) to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation Therapy) for their disease.
Trial Details
NCT Number NCT07339943
Lead Sponsor University Health Network, Toronto
Collaborators: Exact Imaging, Clinical Laserthermia Systems AB
Conditions Prostate Cancer (Adenocarcinoma), Low and Intermediate Risk Prostate Cancer
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov